PPT-thalidomide

Health Law and Bioethics 2014 By Ana Granadeiro 1 background The release of thalidomide in the 1950s and 1960s led to the worlds most publicised pharmaceutical disaster. FEATURE Dr V Pannikar, Medical Officer, Communicable Group), WHO History Thalidomide or phthalimido) glutarimide was marketed in 1957 for morning sickness and nausea and soon became the ‘drug o U*bm@epn@ef U*fsbQz of Thalidomide? Who Should Not Take Thalidomide? 15How Is Thalidomide Given? Can Thalidomide Be Taken With Other Cancer Treatments? 17Will Insurance Cover the Cost of Thalido 1 Report of a meeting of experts World Health Organization (WHO) Geneva, 2014 2 CONTENTS Opening ................................ ................................ ................................ .... ). A. Portu. 1,2. , I. Postuma. 3,4. , M.A. Gadan. 1. , G. Saint Martin. 1. , M.S. Olivera. 1. , S. Altieri. 3,4. , . S. Bortolussi. 3,4. 1 – 2 – . 3. – 4 – . Stereochemistry. Many biomolecules, including proteins, carbohydrates and DNA, are chiral. . A typical drug molecule acts by docking with a target biomolecule such as an enzyme or receptor. These drugs are often chiral, and the two enantiomers may differ greatly in efficacy.. Thalidomide was found to be unsafe for pregnant women as it affected their developing foetuses. Many women who took the drug gave birth to babies with severe limb deformities. . Later on Doctors discovered thalidomide could cure leprosy and started for patient suffering with the disease in the developing world. But again children were born with abnormalities.. DATA SHEET THALOMID Teratogenic effects: Thalidomide has caused severe birth defects when taken during pregnancy. Thalidomide should never be used by women who are pregnant or who could become pregn Rates of VTE* in Newly Diagnosed MM . Treatment. No Prophylaxis. Any Prophylaxis. ASA. Warfarin. 1-1.25 mg/d. Prophylactic LMWH. Therapeutic Anticoagulation. T alone . (95% CI) . 1.3 . (0.4–2.7) . Rates of VTE* in Newly Diagnosed MM . Treatment. No Prophylaxis. Any Prophylaxis. ASA. Warfarin. 1-1.25 mg/d. Prophylactic LMWH. Therapeutic Anticoagulation. T alone . (95% CI) . 1.3 . (0.4–2.7) . Pierpaolo Andriani. Kedge Business School, France. Email: pier2paolo@gmail.com. Part of this work has been done in collaboration with Mariano Mastrogiorgio and . Ayfer. Ali. Definition . “We suggest that such characters, evolved for other usages (or for no function at all), and later “coopted” for their current role, be called . Dr. . M.V.Raghavendra. . Rao. ,. Professor of Medical . Microbiology, Immunology and . Parasitology,. Dean (Students Affairs). Avalon University School of Medicine. Sta. . Rosaweg. 122-124. Willemstad, . Copenhagen. , . June 11. th. . 2016. EU Drug Approval and Reimbursement Policy. No standardized. cost-benefit formula exists across the EU. . The Estonian reimbursement committee (Estonian Health Foundation) initially (2013) . unexpected and serious damage.  to unborn babies in the 1950s and 1960s. Thalidomide was developed as a sleeping pill, but it was also thought to be useful for easing morning sickness in pregnant women. Unfortunately, it had not been tested for use in this way.. Continued. Pharmaceutical Discoveries and Problems. Insulin Discovered . Diabetes mellitus (sweetened with honey). Medical . researcher Frederick . Banting. and research assistant Charles Best . Isolated insulin and successfully .